Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Congress authorized the FDA to determine whether a drug is “in shortage in the United States.” The FDA’s determination of a drug shortage ...

The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

We recently published a list of the 11 Best Pharma Stocks to Buy According ... treatment through targeted alpha therapies. By ...

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs Zepbound ... the shortage list based only ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...